Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study

References

• Proft F, Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Ther Adv Musculoskelet Dis. 2018;10(5–6):129–139.
   PubMed Web of Science ®Google Scholar
• Shahinyan A, Margaryan L, Samuel S. Ankylosing spondylitis. Abd-Elsayed A, editor. Pain Cham Switzerland: Springer International Publishing; 2019. p. 1239–1241.
   Google Scholar
• de Winter Jj, Paramarta JE, de Jong Hm, et al. Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis. RMD Open. 2019;5(1):e000802.
   PubMed Web of Science ®Google Scholar
• Wenker KJ, Quint JM Ankylosing Spondylitis. In: StatPearls. StatPearls Publishing; 2021. Accessed 2021 Jul 28. http://www.ncbi.nlm.nih.gov/books/NBK470173/
   Google Scholar
• Olivieri I, D’Attino R, Gualberti G, et al. THU0398 observational study on the quality of life of Italian axial spondyloarthritis patients (QUASAR): baseline data. Ann Rheum Dis. 2016;75(Suppl 2):332.
   PubMed Web of Science ®Google Scholar
• Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology. 2014;53(4):650–657.
   PubMed Web of Science ®Google Scholar
• De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol. 2007;36(4):14–21.
   PubMed Web of Science ®Google Scholar
• Olivieri L, Salvarani C, Cantini F, et al. Recommendations for starting anti TNF-α in patients with ankylosing spondylitis. Reumatismo. 2003;55(4):220–223.
   PubMedGoogle Scholar
• Wolf M, Weber M-A. Inflammatory and infectious disorders of the spine. In: Barkhof F, Jager R, Thurnher M, et al., editors. Clinical neuroradiology: the ESNR textbook. Cham Switzerland: Springer International Publishing; 2019. p. 1–29.
   Google Scholar
• Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology. 2020;59(Supplement_4):iv79–iv89.
   PubMed Web of Science ®Google Scholar
• der Heijde D V, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–991
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Ceribelli A, Marotto D, et al. Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev. 2019;18(6):583–592.
   PubMed Web of Science ®Google Scholar
• So A, Inman RD. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):453–471.
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al. Update of the American college of rheumatology/spondylitis association of america/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–1613.
   PubMed Web of Science ®Google Scholar
• Navarro-Compan V, Plasencia-Rodriguez C, de Miguel E, et al. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open. 2017;3(2):e000524.
   PubMed Web of Science ®Google Scholar
• Tahir H. Therapies in ankylosing spondylitis-from clinical trials to clinical practice. Rheumatology (Oxford). 2018;57(suppl_6):vi23–8.
   PubMed Web of Science ®Google Scholar
• Hunter T, Schroeder K, Sandoval D, et al. Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Ther. 2019;6(2):207–215.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Colombo GL, Di Matteo S, Martinotti C, et al. Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. Clinic Outcomes Res. 2018; 10: 477–491.
   PubMed Web of Science ®Google Scholar
• Misra DP, Agarwal V. Real-world evidence in rheumatic diseases: relevance and lessons learnt. Rheumatol Int. 2019;39(3):403–416.
   PubMed Web of Science ®Google Scholar
• https://www.reumatologia.it/cmsx.asp?IDPg=983 [cited 2020 Sep 7].
   Google Scholar
• Pascal C, Fagnani F, Cukierman G, et al. Burden of Severe Spondyloarthritis in France: a Nationwide Assessment of Prevalence, Associated Comorbidities and Cost. Joint Bone Spine. 2019;86(1):69–75.
   PubMed Web of Science ®Google Scholar
• Quilis N, Sivera F, Seoane-Mato D, et al. Prevalence of Ankylosing Spondylitis in Spain: EPISER2016 Study. Scand J Rheumatol. 2020;49(3):210–213.
   PubMed Web of Science ®Google Scholar
• Braun J, Schwarting A, Hammel L, et al. [Medical care situation of patients with ankylosing spondylitis and psoriatic arthritis in Germany: medical care situation of patients with spondyloarthritis (SpA): ankylosing spondylitis (AS) and psoriatic arthritis (PsA) from the perspective of rheumatologists in private practice and hospitals in Germany-Results of the research project “SpA Loop-Life of Outpatients”]. Z Rheumatol. 2019;78:372–81. Barczyńska TA, Węgierska M, Żuchowski P, et al. Coexistence of rheumatoid arthritis and ankylosing spondylitis. Reumatologia. 2015;53:279-285.
   Web of Science ®Google Scholar
• Garrido-Cumbrera M, Navarro-Compán V, Zarco P, et al.Atlas of axial spondyloarthritis in Spain 2017: study design and population.English Edition.2019;15(3):127–132 Reumatología Clínica
   Google Scholar
• D’Angelo S, Gilio M, D’Attino R, et al. Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data. Clin Exp Rheumatol. 2019;37(5):1599–1613.
   Web of Science ®Google Scholar
• Machado PM, Landewe R, Heijde DV. Assessment of SpondyloArthritis International Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539–1540.
   PubMed Web of Science ®Google Scholar
• Marin J, Acosta Felquer ML, Soriano ER. Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy. Open Access Rheumatol. 2018;10:33–41.
   PubMed Web of Science ®Google Scholar
• Ørnbjerg LM, Brahe CH, Askling J, et al. Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019;78(11):1536–1544.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29:664–674.
   PubMed Web of Science ®Google Scholar
• Lie E, Van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70(1):157–163.
   PubMed Web of Science ®Google Scholar
• Alvarez-Madrazo S, Kavanagh K, Stefan S, et al. Discontinuation, Persistence and Adherence to Subcutaneous Biologics Delivered via a Homecare Route to Scottish Adults with Rheumatic Diseases: a Retrospective Study. BMJ Open. 2019;9(9):e027059.
   PubMed Web of Science ®Google Scholar
• Lyu R, Govoni M, Ding Q, et al. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol Int. 2016;36(1):143–153.
   PubMed Web of Science ®Google Scholar
• Arends S, Brouwer E, Van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13(3):R94.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Van der Heijde D, Karki C, et al. Tumor necrosis factor inhibitor discontinuation in patients with ankylosing spondylitis: an observational study from the US-based Corrona registry. Rheumatol Ther. 2018;5(2):537–550.
   PubMed Web of Science ®Google Scholar
• Fabbroni M, Cantarini L, Caso F, et al. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. 2014;2014:862969.
   PubMed Web of Science ®Google Scholar